EGFR and Pleural effusion: The phase 2 WJOG9717L trial (Randomized phase II study of osimertinib plus bevacizumab and osimertinib for chemotherapy-naive patients with nonsquamous non-small cell lung cancer harboring EGFR mutations) compared osimertinib plus bevacizumab combination therapy with osimertinib monotherapy in untreated patients having advanced EGFR-mutated NSCLC with or without concomitant pleural effusion.